Shanghai Bio-heart Biological Technology Co (HKSE:02185) Risk Assessment

View and export this data going back to 2021. Start your Free Trial

What is Shanghai Bio-heart Biological Technology Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Shanghai Bio-heart Biological Technology Co is: No Data: Cannot be evaluated.

Competitive Comparison of Shanghai Bio-heart Biological Technology Co's Risk Assessment

For the Biotechnology subindustry, Shanghai Bio-heart Biological Technology Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Bio-heart Biological Technology Co's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Bio-heart Biological Technology Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Shanghai Bio-heart Biological Technology Co's Risk Assessment falls into.

Shanghai Bio-heart Biological Technology Co (HKSE:02185) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Shanghai Bio-heart Biological Technology Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Shanghai Bio-heart Biological Technology Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Bio-heart Biological Technology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Bio-heart Biological Technology Co Ltd (HKSE:02185) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.590 Ruiqing Road, Room 302, 3rd Floor, Building 4 & Building 6, East Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN

Website

http://www.bio-heart.com

Shanghai Bio-heart Biological Technology Co Ltd is engaged in the research and development of bioresorbable scaffold (BRS) products and the renal denervation (RDN) system. The company is a interventional cardiovascular device company in China, and locate in Shanghai Zhangjiang Hi-Tech Park Medical Device Industrial Park. Focused on two therapies, bioresorbable scaffolds (BRS) and renal denervation (RDN), addressing the unmet medical needs of Chinese patients for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension.

Executives

Tpg Operating Group Ii, L.p.	2201 Interest of corporation controlled by you
Chen Hao	2201 Interest of corporation controlled by you
Zhu Linan	2201 Interest of corporation controlled by you
Wang Nengguang	2201 Interest of corporation controlled by you
Union Season Holdings Limited	2201 Interest of corporation controlled by you
Sk China Company Limited	2201 Interest of corporation controlled by you
Right Lane Limited	2201 Interest of corporation controlled by you
Proud Solar Limited	2201 Interest of corporation controlled by you
Magic Grace Limited	2101 Beneficial owner
Loft Success Investments Limited	2201 Interest of corporation controlled by you
Lc Healthcare Fund Ii, L.p.	2201 Interest of corporation controlled by you
Lc Healthcare Fund Ii Gp Limited	2201 Interest of corporation controlled by you
Lc Fund Gp Limited	2201 Interest of corporation controlled by you
Great Unity Fund I, L.p.	2201 Interest of corporation controlled by you
Lian Xiang Kong Gu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you

Shanghai Bio-heart Biological Technology Co Headlines

No Headlines